Dr. Larson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1275 York Ave
New York, NY 10021Phone+1 212-639-7373Fax+1 212-717-3263- Is this information wrong?
Education & Training
- Virginia Mason Franciscan HealthResidency, Internal Medicine, 1968 - 1970
- University of Washington School of MedicineClass of 1968
- University of WashingtonB.A., Zoology, 1959 - 1963
Certifications & Licensure
- DC State Medical License 1986 - Present
- OR State Medical License 1975 - Present
- NJ State Medical License 2006 - 2025
- NY State Medical License 1988 - 2025
- WA State Medical License 1969 - 2024
- MD State Medical License 1972 - 1996
- American Board of Internal Medicine Internal Medicine
- American Board of Nuclear Medicine Nuclear Medicine
Awards, Honors, & Recognition
- Benedict Cassen Prize for Research in Nuclear Medicine 2012
- Castle Connolly Top Doctor 2012
- New York, Super Doctor 2011
- Join now to see all
Clinical Trials
- PET Scan in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 1997 Jan 01
- PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery Start of enrollment: 1998 May 01
- Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer Start of enrollment: 2004 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- Patient metabolic profile defined by liver and muscleF-FDG PET avidity is independently associated with overall survival in gastric cancer.Gönen, M., Vitiello, G., Jayaprakasam, V., Tang, L., Schattner, M., Janjigian, Y., Ku, G., Maron, S., Schoder, H., Larson, S., Datta, J., Coit, D., Brennan, M., Strong...> ;Gastric Cancer. 2024 Mar 4
- Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dos...Lisa Bodei, R Michael Tuttle, Ravinder K Grewal, Audrey Mauguen, Finn Augensen, Murad Abusamra, Sonia Mahajan, Vetri Sudar Jayaprakasam, Joseph R Osborne, Sofia Haque,...> ;European Journal of Nuclear Medicine and Molecular Imaging. 2024 Jan 1
- 4 citationsEfficacy of HER2-Targeted IntraperitonealAc α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis.Sebastian K Chung, Daniela Burnes Vargas, Christopher S Chandler, Sumudu Katugampola, Darren R Veach, Michael R McDevitt, Shin H Seo, Brett A Vaughn, Sara S Rinne, Ble...> ;Journal of Nuclear Medicine. 2023 Sep 1
- Join now to see all
Journal Articles
- Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid CancersSteven M Larson, Sofia Haque, Duan Li, R Michael Tuttle, Mona M Sabra, Alan L Ho, Eric J Sherman, Ravinder K Grewal, James A Fagin, David G Pfister, Ronald A Ghossein, The Journal of Clinical Endocrinology and Metabolism
- Bone metastases in castration-resistant prostate cancer: expression on PET and overall survivalVargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H, Radiology, 1/1/2014
- Phase II study of lutetium-177 labeled anti-prostate-specific membraneantigen (PSMA) monoclonal antibody J591 for metastatic castration-resistantprostate cancerTagawa ST, Milowsky MI, Morris MJ, Vallabhajosula S, Christos PJ, Akhtar NH, Goldsmith SJ, Osborne J, Larson SM, Pandit-Taskar N, Scher HI, Bander NH, Nanus DM, Clin Cancer Res, 1/28/2013
- Join now to see all
Books/Book Chapters
Lectures
- Harnessing the Power of the Atom for the Theranostics of Oncology: Targeted Radiotherapy and diagnosisNew Haven, CT - 1/23/2015
- Tumor Immunology-Multidisciplinary Science Driving Combination TherapyBanff, Alberta, Canada - 1/8/2015
- Androgen Receptor Imaging AgentsBaltimore, MD - 1/4/2015
- Join now to see all
Press Mentions
- Steven M. Larson, M.D., Receives SNMMI 2021 Paul C. Aebersold AwardJune 14th, 2021
- New Nuclear Medicine Approach Shows Potential for Precision Treatment of Solid TumorsJune 26th, 2018
Grant Support
- 124i-Cg250 Immunopet Imaging Of Sunitinib Treatment Response In Renal Cell CancerNational Cancer Institute2011
- Mskcc Center For Molecular Imaging In CancerNational Cancer Institute2008–2011
- Imaging CoreNational Cancer Institute2008–2011
- Molecular Imaging Of Castrate- Resistance Metastatic Prostate CancerNational Cancer Institute2008–2010
- Biophysics And Nuclear MedicineNational Cancer Institute2008–2009
- Shared Instrument: Focus Micropet: CancerNational Center For Research Resources2005
- Shared Instrument: Focus MicropetNational Center For Research Resources2005
- Mskcc Center For In Vivo Molecular Imaging In CancerNational Cancer Institute2003–2005
- Core--ImagingNational Cancer Institute2002
- Imaging Markers Of Progression &Response In Prostate CancerNational Cancer Institute2000–2002
- Core--Pet/Gamma ImagingNational Cancer Institute2000–2002
- Core--Biophysics And Nuclear MedicineNational Cancer Institute2000–2002
- Core--Nuclear Medicine CoreNational Cancer Institute1996–1999
- Monoclonal Antibody Imaging And TherapyNational Cancer Institute1996–1997
- Small Instrumentation ProgramNational Cancer Institute1989
Professional Memberships
- Member
- Member
Hospital Affiliations
- NYC Health + Hospitals / BellevueNew York, New York
- Memorial Sloan Kettering Cancer CenterNew York, New York
External Links
- My Bibliographyhttp://www.ncbi.nlm.nih.gov/sites/myncbi/steven.larson.1/bibliography/47640692/public/?sort=date&direction=ascending
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: